Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2001-10-05
2002-10-01
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S559000
Reexamination Certificate
active
06458839
ABSTRACT:
BACKGROUND
Columnar epithelia exist in the lungs, kidneys, bladder, bile ducts, pancreatic ducts, gall bladder, testicles, thyroid, trachea, intestine, stomach, and liver. In many disease states, polymorphonuclear leukocytes (PMN) migrate across these epithelia. (Yardley J. H., et al. (1977).
In The Gastrointestinal Tract.
Yardley and B. C. Morson, editors. Williams and Wilkins Co., Baltimore. 57.) (Yardley, J. H. (1986).
In Recent Developments in the Therapy of Inflammatory Bowel Disease. Proceedings of a Symposium.
Myerhoff Center for Digestive Disease at Johns Hopkins, Baltimore. 3-9.) This migration of PMN is an early event in the mechanism of epithelial perturbation, which includes one or more of the following events: abnormal fluid and electrolyte transport, specific epithelial barrier dysfunction, and ultimately mucosal breakdown. These perturbations lead to chronic and episodic inflammatory conditions.
Epithelial perturbations cause or contribute to many inflammatory disease states including: gastritis, diverticulitis, cystic fibrosis, infectious colitis, bronchitis, asthma, Crohnis disease, nephritis, alveolitis, intestinal ulcers, idiopathic AIDS enteropathy, gastroenteritis, ischemic diseases, and glomerulonephritis. The efficacy of existing therapy for epithelial inflammation, such as methotrexate or corticosteroids, is highly unsatisfactory, partially due to a high toxicity which produces severe, adverse effects such as bone-weakening and systemic immuno-suppression. (Physician's Desk Reference (41st ed., 1987) Medical Economics Co., Inc. 1103-1104.) Even under ideal bioavailability conditions, the existing treatments fail to mechanistically target columnar epithelial inflammation.
New treatments for epithelial inflammation are needed.
SUMMARY OF INVENTION
This instant invention discloses new methods and compositions for treating or preventing inflammation which is caused or contributed to by the perturbation of columnar epithelia in a subject. The new pharmaceutical compositions comprise natural lipoxin A
4
or analogs of lipoxin A
4.
And the new methods comprise administering to a subject having a columnar epithelial inflammatory disease an effective, antiinflammatory amount of natural lipoxin A
4
or a lipoxin A
4
analog.
Natural lipoxin A
4
and analogs are thought to effect-their anti-inhibitory activity by interfering with the interaction between polymorphonuclear (PMN) cells and columnar epithelium. Migration of PMN is an early event in the mechanism of epithelial perturbation which leads to mucosal breakdown, epithelial dysfunction, and chronic inflammatory conditions. As disclosed herein, prior exposure of polymorphonuclear leukocytes (PMN) to certain lipoxin compounds alters subsequent PMN migration across the columnar epithelium, thereby preventing an inflammatory response. By inhibiting an early event in the mechanism, LXA
4
effectively targets inflammation and inflammatory responses caused or contributed to by epithelial perturbation.
LXA
4
, is a naturally-occuring tetraene-containing eicosanoids. Therefore, pharmaceutical compositions of LXA
4
or analogs thereof would expected to be biocompatible. In addition, because LXA
4
and analogs thereof are highly potent in vivo, relatively small doses can be administered to produce a therapeutic effect. In addition, natural lipoxins are subject to metabolic transformations in situ, that would further minimize any toxic, adverse effects, or adverse drug interactions. Alternatively, the instant invention discloses LXA
4
analogs that are relatively resistant to in vivo degradation and therefore, if shown to be safe, can be administered for a more prolonged therapeutic effect. Lipophilic LXA
4
can be actively absorbed by columnar epithelial tissue.
For the reasons stated above, pharmaceutical compositions of natural LXA
4
or analogs thereof provide a superior drug for treating columnar epithelial inflammatory diseases. Additional features and advantages of the invention will become more apparent from the following detailed description and claims.
REFERENCES:
patent: 4560514 (1985-12-01), Samuelsson et al.
patent: 4576758 (1986-03-01), Morris
patent: 5049681 (1991-09-01), Sato
patent: 5079261 (1992-01-01), Sahran et al.
patent: 62-198677 (1987-09-01), None
patent: 63-88153 (1988-04-01), None
patent: 1-228994 (1989-09-01), None
patent: 3-227922 (1991-10-01), None
Badr, K.F., “15-Lipoxygenase Products as Leukotriene Antagonists: Therapeutic Potential in Glomerulonephritis”,Kidney International(1992) vol. 42, Supp. 38, pp. S101-S108.
Dahlen, S-E., “Lipoxins and other Lipoxygenase Products with Relevance to Inflammatory Reactions in the Lung”,Annals of the New York Academy of Sciences, Advances in the Understanding and Treatment of Asthma (no date available), pp. 262-273.
Fiore, S., “The Lipoxin Biosynthetic Circuit and their Actions with Human Neutrophils” (1991),Advances in Experimental Medicine and Biology, vol. 314, pp. 109-132.
Fiore, S., et al., “Induction of Functional Lipoxin A4 Receptors in HL-60 Cells”,Blood(1993), vol. 81, No. 12, pp. 3395-3403.
Lederman, S., et al., “Identification of a Novel Surface Protein on Activated CD4+ T Cells that Induces Contact-Dependent B Cell Differentiation (Help)”,J. Exp. Med.(1992), vol. 175, pp. 1091-1101.
Madara, J.L., et al. “A Simple Approach to Measurement of Electrical Parameters of Cultured Epithelial Monolayers: Use in Assessing Neutrophil-Epithelial Interactions”,J. Tiss. Cult. Meth.(1992), vol. 14, pp. 209-216.
Madara, J.L. et al., “5′-Adenosine Monophosphate is the Neutrophil-derived Paracrine Factor that Elicits Chloride Secretion from T84 Intestinal Epithelial Cell Monolayers”,J. Clin. Invest.(1993), vol. 91, pp. 2320-2325.
Nash, S., et al., “Effects of Polymorophonuclear Leukocyte Transmigration on the Barrier Function of Cultured Intestinal Epithelial Monolayers”,J. Clin. Invest.(1987) vol. 80, pp. 1104-1113.
Noelle, R.J., et al. “A 39-kDa Protein on Activated Helper T Cells Binds CD40 and Transduces the Signal for Cognate Activation of B Cells”,Proc. Natl. Acad. Sci. USA(1992) vol. 89, pp. 6550-6554.
Parkos, C.A., et al., “Neutrophil Migration Across a Cultured Intestinal Epithelium”,J. Clin. Invest.(1991) vol. 88, pp. 1605-1612.
Parkos, C.A., et al., “Neutrophil Migration Across a Cultured Epithelial Monolayer Elicits a Biphasic Resistance Response Representing Sequential Effects on Transcellular and Paracellular Pathways”,The Journal of Cell Biology(1992) vol. 117, No. 4, pp. 757-764.
Pettitt, T.R., et al., “Synthesis of Lipoxins and Other Lipoxygenase Products by Macrophages form the Rainbow Trout, Oncorhynchus Mykiss”,The Journal of Biological Chemistry(1991) vol. 266, No. 14, pp. 8720-8726.
Samuelsson, B., “An Elucidation of the Arachidonic Acid Cascade Discovery of Prostaglandins, Thromboxane and Leukotrienes”,Drugs(1987) vol. 33, Supp. 1, pp. 2-9.
Serhan, C.N., “Lipoxins: Eicosanoids Carrying Intra- and Intercelular Messages”,Journal of Bioenergetics and Biomembranes(1991), vol. 23, No. 1, pp. 105-122.
Nicolaou, K.C., et al., “Identification of a Novel 7-cis 11-Trans-Lipoxin A4 Generated by Human Neutrophils: Total Synthesis, Spasmogenic Activities and Comparison with other Geometric Isomers of Lipoxins A4 and B4”,Biochimica et Biophysica Acta(1989) vol. 1003, pp. 44-53.
Nicolaou, K.C., et al., “Total Synthesis of Novel Geometric Isomers of Lipoxin A4 and Lipoxin B4”,Journal of Organic Chemistry(1989) vol. 54, pp. 5527-5535.
Nicolaou, K.C., et al., “Lipoxins and Related Eicosanoids: Biosynthesis, Biological Properties and Chemical Synthesis”,Agnew. Chem. Int. Ed. Engl.(1991), vol. 30, pp. 1100-1116.
Colgan Sean P.
Madara James L.
Serhan Charles N.
Dorsey & Whitney LLP
Fay Zohreh
Rothenberger Scott D.
The Brigham and Women's Hospital
LandOfFree
Modulation of inflammation related to columnar epithelia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of inflammation related to columnar epithelia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of inflammation related to columnar epithelia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2964468